WoundClear

Marine-based enzymatic treatment for severe wound debridement

™

REG410

Wound healing

LCE from trout • Enzymatic debridement• Novel drug

Phase 1

Pre-Clinical

Phase 2

Phase 3

Discovery

WoundClear™ is a novel, marine-based enzymatic drug, intended to aid in debridement of severe wounds.

Partial and full-thickness wounds with eschar development, in conjunction with or as stand-alone debridement therapy
Trauma wounds (abrasions, lacerations, second-degree burns, skin tears)
Pressure ulcers
Chronic vascular ulcers
Diabetic ulcers

WoundClear™ utilizes the LCE1 fusion protein from trout to facilitate debridement of eschar (necrotic tissue) in severe wounds. It is currently in the discovery stage.

WoundClear™ development is led by Regenics, and supported by researchers at RISE AB (Sweden).

WoundClear™ is intended to support treatment of:

A quick summary of WoundClear™

Natural ingredients

A novel marine-based treatment for severe wound debridement.

LCE from trout

Indication

Severe wound debridement

Stage

Discovery

Collex® is an advanced wound dressing containing HTX™, designed to aid healing of partial thickness burns and chronic wounds.

Vernex® is an HTX™-based hydrogel wound spray, intended for treatment of partial thickness burns and chronic wounds.

Other products

Vernex

Collex